What's more, CheckMate 227 was a Phase III study that aimed to evaluate the effects of ICI‐based treatment in patients with NSCLC with a high tumor mutational burden and revealed encouraging clinical results regardless of PD‐L1 status (PD‐L1 TPS <1% or ≥1%; Hellmann et al., 2018). The gene discussed is CD274; the disease is neoplasm.